|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Jim Cramer is avoiding cyclical trades like Freeport McMoRan and Caterpillar, and instead opting for companies he can own longer term, such as Under Armour, PayPal, Visa and MasterCard.
One of these biopharma executives, or the grouped nominees, will win the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO. Here are the best biopharma CEOs.
Catch up on Jim Cramer's ideas from this past week, when he wrote about why he's bullish on biotechs, and why he's not worried about the Fed punishing manufacturing.
Jim Cramer shares his views on China's effect on biotech and pharma. Celgene, Pfizer, Regeneron and Receptos are among the many stocks discussed here.
Today's spike in oil prices was even strong enough to embolden money managers to do some buying, Cramer says.
These stocks have had a really good run, says Wedbush Securities, which is holding its annual health care investment conference in New York.
Investors are most excited about Bluebird Bio (BLUE) and Pacira Pharmaceuticals (PCRX), according to Wedbush Securities, which is holding its annual healthcare investment conference in New York.
Of the 13 charts overall, seven got an A, one got a B, two are Cs and there are one each for D and F.
For frustated bulls, a looming pullback in CELG would create a low-risk entry point.
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
Jim Cramer shares his views on a really bad day and when a leader stumbles. Freeport McMoRan, Google, Biogen and Capital One are among the many stocks discussed here.
Cramer is delighted to see two of his favorite companies, Celgene and Receptos come together.
Cramer says you've got to listen to the commentary on earnings from Apple tomorrow, not to mention what's up with Microsoft and falling PC sales.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Receptos, Inc.
Jim Cramer shares his views on chasing winners and the classical approach. Netflix, Celgene, Macy's and Goldman Sachs are among the many stocks discussed here.
Catch up on Jim Cramer's ideas from this past week as he talks about this perilous market, why oil bears are wrong, and which sectors portfolio managers fear, but shouldn't.
The Rosen Law Firm, a global investor rights law firm, announces that it is investigating the Board of Directors of Receptos, Inc.
Jim Cramer's responds to viewer Twitter questions. Here's why he's telling investors to buy biotech Celgene, while he's still bearish on AK Steel.
Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
Cramer's takeaway from today's Delivering Alpha conference may sway traditional views of valuing a company.
Kirby McInerney LLP is investigating potential claims against the Board of Directors of Receptos, Inc.
The stock markets in the United States declined today after enjoying four consecutive days of gains. Federal Reserve Chairperson Janet Yellen told the Congress that policymakers were likely to raise i...
Stocks closed lower for the first time in five sessions as Greece's Parliament voted on the latest bailout plan while protesters rioted outside.
Stocks slip into the red by late afternoon Wednesday as returned focus on uncertainty in Greece and Iran overshadow positive news on the U.S. economy.
Celgene (CELG) said it had acquired San Diego-based Receptos (RCPT) for $7.2 billion in cash as it aims to enhance its inflammation and immunology portfolio.
Three biotech stocks are trading on big volume following news that Celgene will acquire Receptos. Here's how to trade them now.